Industry news

This week in pharma.

The latest headlines from across the pharmaceutical industry — refreshed automatically, covering the past seven days.

20 stories this week · updates every 30 minutes

pharmaphorum · about 2 hours ago

Lilly strikes again, buying Calytrix in $1.5bn deal

Read article

pharmaphorum · about 3 hours ago

Gazyva is first FDA-cleared drug for rare disease pMN

Read article

pharmaphorum · about 4 hours ago

AZ's Alexion extends gMG options with two Klygefa approvals

Read article

pharmaphorum · about 4 hours ago

An AAPS PharmSci 360 overview: Making better decisions faster, earlier, with fewer resources

Read article

pharmaphorum · about 5 hours ago

China overtakes Europe in healthcare investing sentiment

Read article

Pharmaceutical Technology · about 6 hours ago

Sofinnova Partners backs European life sciences sector with €725M raise

The main recipients of this fund will be European life sciences companies, though some across the US and other geographies will also benefit.

Read article

Pharmaceutical Technology · about 6 hours ago

AstraZeneca secures FDA approval for Imfinzi combo in MIBC

The US FDA has approved AstraZeneca's Imfinzi in combination with enfortumab vedotin for adult patients with MIBC who cannot receive or have refused cisplatin-based chemotherapy.

Read article

Pharmaceutical Technology · about 6 hours ago

FDA rejects Summit’s ivonescimab application for lung cancer

The US FDA has declined to approve Summit Therapeutics’ BLA for ivonescimab in patients with locally advanced or metastatic NSCLC.

Read article

pharmaphorum · about 6 hours ago

Catching the signals sooner: AI’s role in proactive pharmacovigilance

Read article

Pharmaceutical Technology · about 12 hours ago

HLTH 2026: Potential 2028 US presidential contender Mark Kelly warns pharma over profits

Following the 2026 US midterm elections, Democrats are putting healthcare affordability, drug pricing and insurance coverage at the centre of their agenda. Speaking at HLTH USA in Las Vegas, Senator Mark Kelly also hi…

Read article

pharmaphorum · about 21 hours ago

FDA won't approve Summit, Akeso's ivonescimab

Read article

Pharmaceutical Technology · 3 days ago

AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT

KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.

Read article

Pharmaceutical Technology · 3 days ago

AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence

Real-world semaglutide CV outcomes mirror clinical trials, with greater treatment persistence linked to better outcomes.

Read article

pharmaphorum · 3 days ago

Closing the global evidence gap in oncology, with Flatiron Health

Read article

Pharmaceutical Technology · 3 days ago

BIO Europe: Financing, AI and geopolitics shape biotech discourse

Speakers at BIO-Europe 2026 noted that European biotechs must be agile and adaptable in times of geopolitical and financial upheaval.

Read article

pharmaphorum · 3 days ago

Windward Bio catches $175m from its IPO

Read article

Pharmaceutical Technology · 3 days ago

FDA puts commissioner’s priority voucher framework on ice

Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.

Read article

Pharmaceutical Technology · 3 days ago

Neurosterix pockets $105m to advance neuropsychiatry pipeline

Neurosterix hopes that NTX-253 may compete with BMS’s Cobenfy as the schizophrenia field explores mechanisms past dopamine modulation.

Read article

Pharmaceutical Technology · 3 days ago

BMS sets unified research and development structure for 2027

Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.

Read article

Get the weekly round-up

Join our mailing list for industry news and Smartcare updates.

Headlines link to their original publishers, including pharmaphorum and Pharmaceutical Technology.